Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the key myeloproliferative neoplasms (MPNs) data to look out for at EHA 2020. Specifically mentioned are novel therapies and pitfalls in MPNs, parsaclisib and mepolizumab for hypereosinophilic syndrome. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).